A UK-based biotechnology company working to enable new generation of mitochondrial engineering technologies and therapeutics

MitoExport Limited (Cambridge UK) is bioengineering a first-in-class platform (MitoExporter) for programmable and selective export of untransplanted or unengineered mitochondria. MitoExporter would enabling long-term maintenance and fine-tuning of engineered mtDNA at defined heteroplasmies in vivo.We aim to develop novel, UK-based therapeutic modalities with other Precision Mitochondria participants based on synergies between MitoExporter and mitochondrial secretion and transplantation or engineering approaches. MitoExporter also has vast potential as a standalone technology platform and therapeutic, including for the removal of damaged mitochondria. Indeed, it has been proposed that damaged mitochondria would be the most important cellular component to export out of cells (with the biggest therapeutic benefits) by MitoExporter. A long-term aim of MitoExport Limited is to start clinical trials for age-related diseases, including Alzheimer’s disease.We are currently looking for funding opportunities to develop MitoExporter before accepting investments.Our founder, Bjorn Fraser Olaisen, is a molecular geneticist who has developed cellular technologies and worked on various genetics research project (including mitophagy and epigenetic aging) at Universities and with Altos Labs. He is mentored by Fifty Years VC, which organised the 5050 UK company building programme, backed by the Advanced Research + Invention Agency (ARIA). Other mentors include Prof Sir Tony Kouzarides and Rodrigo Santos.Contact: [email protected]